Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II trial of multiple escalating doses of ITI 007 for the treatment of patients with stable schizophrenia.

Next Previous
Trial Profile

Phase Ib/II trial of multiple escalating doses of ITI 007 for the treatment of patients with stable schizophrenia.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lumateperone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Intra-Cellular Therapies

Most Recent Events

  • 30 Jul 2010 Primary endpoints of 'safety and tolerability' have been met; results reported in an Intra-Cellular Therapies media release.
  • 30 Jul 2010 Status changed to completed according to Intra-Cellular Therapies media release
  • 30 Jul 2010 Results have been reported in an Intra-Cellular Therapies media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top